Related Experiment Video
Updated: Apr 13, 2026
High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors
Published on: March 22, 2011
Potent and long-term antiangiogenic efficacy mediated by FP3-expressing oncolytic adenovirus
Il-Kyu Choi1, Hyewon Shin1, Eonju Oh1
1Department of Bioengineering, College of Engineering, Hanyang University, 222 Wangsimni-ro, Seongdong-Gu, Seoul, Korea.
Abstract:
Various ways to inhibit vascular endothelial growth factor (VEGF), a key facilitator in tumor angiogenesis, are being developed to treat cancer. The soluble VEGF decoy receptor (FP3), due to its high affinity to VEGF, is a highly effective and promising strategy to disrupt VEGF signaling pathway. Despite potential advantage and potent therapeutic efficacy, its employment has been limited by very poor in vivo pharmacokinetic properties. To address this challenge, we designed a novel oncolytic adenovirus (Ad) expressing FP3 (RdB/FP3). To demonstrate the VEGF-specific nature of RdB/FP3, replication-incompetent Ad expressing FP3 (dE1/FP3) was also generated. dE1/FP3 was highly effective in reducing VEGF expression and functionally elicited an antiangiogeneic effect. Furthermore, RdB/FP3 exhibited a potent antitumor effect compared with RdB or recombinant FP3. Consistent with these data, RdB/FP3 was shown to greatly decrease VEGF expression level and vessel density and increase apoptosis in both tumor endothelial and tumor cells, verifying potent suppressive effects of RdB/FP3 on VEGF-mediated tumor angiogenesis in vivo. Importantly, the therapeutic mechanism of antitumor effect mediated by RdB/FP3 is associated with prolonged VEGF silencing efficacy and enhanced oncolysis via cancer cell-specific replication of oncolytic Ad. Taken together, RdB/FP3 provides a new promising therapeutic approach in the treatment of cancer and angiogenesis-related diseases.
Insights
A novel oncolytic adenovirus expressing a VEGF decoy receptor (RdB/FP3) effectively targets tumor angiogenesis. This approach prolongs VEGF silencing and enhances oncolysis, offering a promising cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Background:
- Vascular endothelial growth factor (VEGF) is crucial for tumor angiogenesis.
- VEGF decoy receptor (FP3) shows promise but has poor in vivo pharmacokinetics.
- Targeting VEGF signaling is a key cancer treatment strategy.
Purpose of the Study:
- To develop a novel oncolytic adenovirus (RdB/FP3) expressing FP3 to overcome pharmacokinetic limitations.
- To evaluate the anti-angiogenic and anti-tumor efficacy of RdB/FP3 in vivo.
- To elucidate the therapeutic mechanism of RdB/FP3.
Main Methods:
- Generation of an oncolytic adenovirus (RdB/FP3) and a replication-incompetent control (dE1/FP3) expressing FP3.
- Assessment of VEGF expression reduction and anti-angiogenic effects by dE1/FP3.
- Evaluation of anti-tumor effects, tumor vessel density, and apoptosis induction by RdB/FP3 in vivo.
- Analysis of VEGF silencing duration and oncolysis.
Main Results:
- dE1/FP3 effectively reduced VEGF expression and demonstrated anti-angiogenic effects.
- RdB/FP3 exhibited superior anti-tumor efficacy compared to control groups (RdB or recombinant FP3).
- RdB/FP3 significantly decreased tumor VEGF levels, vessel density, and increased apoptosis, confirming in vivo anti-angiogenic activity.
- Therapeutic effects were linked to sustained VEGF silencing and enhanced cancer cell-specific oncolysis.
Conclusions:
- RdB/FP3 represents a promising therapeutic strategy for cancer by effectively inhibiting VEGF-mediated angiogenesis.
- The combination of FP3 delivery via oncolytic adenovirus overcomes pharmacokinetic challenges.
- This approach offers a novel therapeutic avenue for cancer and angiogenesis-related diseases.
